NK:IO

Executive Summary

NK:IO is a UK-based biotechnology company founded in 2018 that is reimagining cancer treatment by harnessing the innate immune system. The company is developing groundbreaking Natural Killer (NK) cell and small molecule therapies targeting both haematological and solid tumours. Its technologies are built on pioneering research from Imperial College London. As a pre-clinical stage company, NK:IO is focused on advancing its lead programs toward clinical trials. The company aims to leverage its unique innate immune platform to address significant unmet needs in oncology, particularly in indications where conventional therapies have failed. While still in early stages, NK:IO's innovative approach positions it as a potential player in the cell therapy space, though it faces typical risks associated with early-stage biotech, including funding requirements and regulatory hurdles.

Upcoming Catalysts (preview)

• Q2 2026IND/CTA Filing for Lead NK Cell Therapy Program30% success
• Q4 2025Preclinical Data Presentation at Major Oncology Conference60% success
• Q1 2026Series A Funding Round Completion50% success